TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07188558: A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting CD19/CD20 CAR T-Cell Product Candidate, Vs. Investigator's Choice of CD19 CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma in the Second-line Setting

Sponsor: Lyell Immunopharma, Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 400 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$3,936,240

Rescue Site Savings

+$2,624,160

Unlock Full NCT07188558 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07188558 Rescue Dossier →